Cutaneous Lupus Erythematosus Clinical Trial
— LAVENDEROfficial title:
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus Who Are Refractory and/or Intolerant to Antimalarial Therapy
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with cutaneous lupus erythematosus (CLE).
Status | Not yet recruiting |
Enrollment | 460 |
Est. completion date | December 21, 2027 |
Est. primary completion date | December 21, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Key inclusion criteria: - Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and histologically confirmed with the following: - CLASI-A total score = 10 points at Screening and confirmed at randomization. - CLA-IGA-R erythema score of = 3 and CLA-IGA-R-OMC score of = 1 at Screening and confirmed at randomization. - Inadequate response or intolerant to antimalarial therapy. - Participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest CT scan result. - Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. - Participants should have a coronavirus disease 2019 (COVID-19) negative PCR or antigen test result as per local policies at Screening. Key exclusion criteria: - History or evidence of suicidal ideation. - Severe or life-threatening Systemic lupus erythematosus (SLE). - Active SLE or Sjögren's Syndrome. - Any active skin conditions other than CLE that may interfere with the study. - History of recurrent infection requiring hospitalization and IV antibiotics. - COVID-19 infection - Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies. - At screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total bilirubin, serum creatinine etc. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply |
Country | Name | City | State |
---|---|---|---|
Argentina | Research Site | Ciudad de Buenos Aires | |
Argentina | Research Site | Córdoba | |
Argentina | Research Site | Quilmes | |
Australia | Research Site | Box Hill | |
Australia | Research Site | Westmead | |
Australia | Research Site | Woolloongabba | |
Austria | Research Site | Innsbruck | |
Austria | Research Site | Linz | |
Austria | Research Site | Sankt Pölten | |
Brazil | Research Site | Belo Horizonte | |
Bulgaria | Research Site | Sofia | |
Chile | Research Site | Santiago | |
China | Research Site | Baotou | |
China | Research Site | Beijing | |
China | Research Site | Beijing | |
China | Research Site | Chongqing | |
China | Research Site | Guangzhou | |
China | Research Site | Hangzhou | |
China | Research Site | Jinan | |
China | Research Site | Nanjing | |
China | Research Site | Shanghai | |
China | Research Site | Shijiazhuang | |
China | Research Site | Wuhan | |
Colombia | Research Site | Barranquilla | |
Colombia | Research Site | Chia | |
France | Research Site | Lyon Cedex 03 | |
France | Research Site | Nice | |
France | Research Site | Paris | |
France | Research Site | Paris | |
France | Research Site | Paris | |
France | Research Site | Paris | |
France | Research Site | Toulouse Cedex 9 | |
Germany | Research Site | Berlin | |
Germany | Research Site | Bochum | |
Germany | Research Site | Dresden | |
Germany | Research Site | Hannover | |
Germany | Research Site | Leipzig | |
Germany | Research Site | Mainz | |
Germany | Research Site | Wuppertal | |
Greece | Research Site | Athens | |
Greece | Research Site | Athens | |
Greece | Research Site | Athens | |
Italy | Research Site | Brescia | |
Italy | Research Site | Florence | |
Italy | Research Site | Napoli | |
Italy | Research Site | Torrette | |
Netherlands | Research Site | Rotterdam | |
Philippines | Research Site | Lipa | |
Philippines | Research Site | Manila | |
Poland | Research Site | Olsztyn | |
Poland | Research Site | Poznan | |
Poland | Research Site | Warszawa | |
Spain | Research Site | Barcelona | |
Spain | Research Site | Madrid | |
Spain | Research Site | Madrid | |
Taiwan | Research Site | Kaohsiung | |
Taiwan | Research Site | Taichung | |
United States | Research Site | Ann Arbor | Michigan |
United States | Research Site | Boston | Massachusetts |
United States | Research Site | Brooklyn | New York |
United States | Research Site | Charlottesville | Virginia |
United States | Research Site | Fort Lauderdale | Florida |
United States | Research Site | Miami | Florida |
United States | Research Site | Miami | Florida |
United States | Research Site | Orange | California |
United States | Research Site | Phoenix | Arizona |
United States | Research Site | Plantation | Florida |
United States | Research Site | Portland | Oregon |
United States | Research Site | Rochester | New York |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca | Parexel |
United States, Argentina, Australia, Austria, Brazil, Bulgaria, Chile, China, Colombia, France, Germany, Greece, Italy, Netherlands, Philippines, Poland, Spain, Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Stage 1 and Stage 2 (US, EU and ROW): Number of participants with adverse events | To evaluate the safety and tolerability of anifrolumab compared with placebo in participants with CLE. | Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (13 weeks from Week 52/ EDV) | |
Primary | Stage 1 and Stage 2 (United States [US]): Number of participants with Cutaneous Lupus Activity of Investigator's Global Assessment-Revised (CLA-IGA-R) erythema score of 0 or 1 and at least a 2- point reduction relative to baseline | The CLA-IGA-R is an assessment tool that scores the three key disease components (erythema; other morphological characteristics [OMC] and follicular activity) of CLE independently. The CLA-IGA-R erythema is scored on a five-point binary scale that provides a global clinical assessment ranging from 0 to 4 (0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe CLE). On all IGA scales, a decrease in score relates to an improvement in signs and symptoms. CLA-IGA-R erythema responder is defined as a participant who achieves a CLA-IGA-R erythema score of 0 or 1 and at least a 2-point reduction relative to baseline. Otherwise, the participant is considered a non-responder. | At Week 24 | |
Primary | Stage 1 and Stage 2 (European Union [EU]/Rest of the World [ROW]: Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score | CLASI is a validated index used for assessing the cutaneous lesions of SLE. The CLASI instrument will be used at each study visit to capture individual skin manifestation scores. CLASI-70 responder (Yes/No) is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. | At Week 24 | |
Secondary | Stage 1 and Stage 2 (US): Number of participants who achieve a CLA-IGA-R OMC score of 0 or 1 and at least a 1-point reduction relative to baseline | The CLA-IGA-R is an assessment tool that scores the three key disease components (erythema; OMC and follicular activity) of CLE independently. The CLA-IGA-R OMC is scored on a five-point binary scale that provides a global clinical assessment ranging from 0 to 4, where 0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe CLE. Assessment of CLA-IGA-R OMC score captures other morphological changes in CLE patients. A decrease in score relates to an improvement in signs and symptoms. A responder (yes/no) is defined as a participant who achieves a CLA-IGA-R OMC score of 0 or 1 and at least a 1-point reduction relative to baseline. Otherwise, the participant is considered a non-responder. | At Week 24 | |
Secondary | Stage 1 and Stage 2 (US): Number of participants who achieve a CLA-IGA-R OMC score of 0. | The CLA-IGA-R is an assessment tool that scores the three key disease components (erythema; OMC and follicular activity) of CLE independently. The CLA-IGA-R OMC is scored on a five-point binary scale that provides a global clinical assessment ranging from 0 to 4, where 0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe CLE. CLA-IGA-R OMC complete response is defined as a participant who scores 0. Otherwise, the participant is a non-responder. Only participants with CLA-IGA-OMC = 3 at baseline will be included in the analysis. | At Week 24 | |
Secondary | Stage 1 and Stage 2 (US): Number of participants with CLA-IGA-R follicular activity score of 0 | The CLA-IGA-R is a tool that scores the three key disease components (erythema; OMC and follicular activity) of CLE independently. CLA-IGA-R follicular activity provides a global clinical assessment on a 2-point binary scale ranging from 0 to 1, where 0 indicates absent and 1 indicates present. On all IGA scales, a decrease in score relates to an improvement in signs and symptoms. A responder (yes/no) is defined as a participant who achieves a CLA-IGA-R follicular activity score of 0. Otherwise, the participant is a non-responder. Only participants with follicular activity score of 1 at baseline will be included in the analysis. |
At Week 24 | |
Secondary | Stage 1 and Stage 2 (EU/ROW): Percent change from baseline in total CLASI-A erythema score | The Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) is a validated index used for assessing the cutaneous lesions of SLE. The CLASI-A erythema score is interpreted as follows: 0-absent; 1-pink; faint erythema; 2-red; 3-dark red; purple/violaceous/crusted/ hemorrhagic | At Week 24 | |
Secondary | Stage 1 and Stage 2 (EU/ROW): Percent change from baseline in total CLASI-A scale/hypertrophy score | The CLASI-A is a validated index used for assessing the cutaneous lesions of SLE. CLASI-A Scale/Hypertrophy can be measured as 0, 1, and 2 where 0 is absent, 1 is scale, and 2 is verrucuos and hypertrohic. | At Week 24 | |
Secondary | Stage 1 and Stage 2 (US): Number of participants with CLA-IGA-R erythema score of 0 or 1 and at least a 2-point reduction relative to baseline, or a CLA-IGA-R OMC score of 0 or 1 and at least a 1-point reduction relative to baseline | The CLA-IGA-R is a tool that scores the three key disease components (erythema; OMC and follicular activity) of CLE independently. The CLA-IGA-R erythema and OMC are scored on a five-point binary scale that provides a global clinical assessment ranging from 0 to 4, where 0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe CLE. A responder (yes/no) is defined as a participant who achieves either a CLA-IGA-R erythema score of 0 or 1 and at least a 2-point reduction relative to baseline, or a CLA-IGA-R OMC score of 0 or 1 and at least a 1-point reduction relative to baseline. Otherwise, the participant is a non-responder. On all IGA scales, a decrease in score relates to an improvement in signs and symptoms. | At Week 24 | |
Secondary | Stage 1 and Stage 2 (US): Number of participants with CLA-IGA-R erythema score of 0 or 1 and at least a 2-point reduction relative to baseline | The CLA-IGA-R is a tool that scores the three key disease components (erythema; OMC and follicular activity) of CLE independently. The CLA-IGA-R erythema is scored on a five-point binary scale that provides a global clinical assessment ranging from 0 to 4 (0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe CLE). A responder is defined as a participant who achieves a CLA-IGA-R erythema score of 0 or 1 and at least a 2-point reduction relative to baseline. Otherwise, the participant is a non-responder. On all IGA scales, a decrease in score relates to an improvement in signs and symptoms. | At Week 12 | |
Secondary | Stage 1 and Stage 2 (US): Number of participants with CLA-IGA-R OMC score of 0 or 1 and at least a 1-point reduction relative to baseline | The CLA-IGA-R is a tool that scores the three key disease components (erythema; OMC, and follicular activity) of CLE independently. The CLA-IGA-R OMC is scored on a five-point binary scale that provides a global clinical assessment ranging from 0 to 4 (0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe CLE). A responder (yes/no) is defined as a participant who achieves a CLA- IGA-R OMC score of 0 or 1 and at least a 1-point reduction relative to baseline. Otherwise, the participant is a non-responder. On all IGA scales, a decrease in score relates to an improvement in signs and symptoms. | At Week 12 | |
Secondary | Stage 1 and Stage 2 (EU/ROW): Number of participants with CLASI-70 response | The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. | At Week 12 | |
Secondary | Stage 1 and Stage 2 (US/EU/ROW): Change from baseline in Skindex-29+3 domain scores | The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. The instrument consists of 33 items, which are used to calculate 4 domains: Symptoms (7 items), Emotions (10 items), Functioning (12 items), and Lupus-specific (3 items). The remaining item asks the participants to rate how often they worry about side effects from treatment; however, this item is not used to calculate the domain scores. The response options are on a 5-point verbal rating scale, ranging from 1 (Never) to 5 (All the time). The instrument has a recall period of the previous 4 weeks. Each domain score ranges from 0 to 100 points, with higher scores indicating worse health-related quality of life. The symptom domain in the Skindex-29+3 evaluates the symptom burden of the disease and includes symptom concepts such as pain, itching, burning, stinging, and sensitivity. | At Week 24 | |
Secondary | Stage 1 and Stage 2 (US/EU/ROW): Serum trough (pre-dose) concentrations of anifrolumab | The Ctrough of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. | Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose) | |
Secondary | Stage 1 and Stage 2 (US/EU/ROW): Number of participants with positive antidrug antibody | The immunogenicity of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. | Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose) | |
Secondary | Stage 1 and Stage 2 (US/EU/ROW): Percent change from baseline in suppression of the Interferon 21-gene | The pharmacodynamics of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. | Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose) | |
Secondary | Stage 2 (US/EU/ROW): Number of participants with = 7-point reduction from baseline in CLASI-A total score | The CLASI is a validated index used for assessing the cutaneous lesions of SLE. It consists of 2 separate scores: i) activity of the disease, and ii) measure of damage. The CLASI instrument will be used at each study visit to capture individual skin manifestation scores. A 7-point reduction CLASI-A is established as clinically meaningful improvement in disease for CLE and as being impactful for patients. Achieving a CLASI-A total score of 9 or below is an accepted threshold for mild disease. | At Week 24 | |
Secondary | Stage 2 (US): Number of participants who are CLA-IGA-R erythema responders from Week 24 up to and including Week 52 | The CLA-IGA-R is an assessment tool that scores the three key disease components (erythema; OMC and follicular activity) of CLE independently. The CLA-IGA-R erythema is scored on a five-point binary scale that provides a global clinical assessment ranging from 0 to 4, where 0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe CLE. On all IGA scales, a decrease in score relates to an improvement in signs and symptoms. Assessment of CLA-IGA-R erythema score captures changes in erythema, a clinically important feature in CLE patients. A responder is defined as a participant who achieves a CLA- IGA-R erythema score of 0 or 1 and at least a 2-point reduction relative to baseline. Otherwise, the participant is a non-responder. Amongst participants randomized to anifrolumab during the double-blind treatment period, the number of participants who maintained a CLA-IGA-R erythema response from Week 24 up to Week 52 will be evaluated. | Up to Week 52 | |
Secondary | Stage 2 (EU): Number of participants who are CLASI-70 responders up to and including Week 52 | The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. Amongst participants randomized to anifrolumab during the double-blind treatment period, the number of participants who maintained a CLASI-70 response from Week 24 up to Week 52 will be evaluated. | Up to Week 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01776190 -
Low-dose UVA1 Radiation in Cutaneous Lupus Patients
|
N/A | |
Completed |
NCT00420173 -
Interdisciplinary Study Group of Lupus Erythematosus (ISGLE)
|
N/A | |
Terminated |
NCT04809623 -
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
|
Phase 1 | |
Completed |
NCT01300208 -
To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus
|
Phase 2 | |
Terminated |
NCT01470313 -
A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus
|
Phase 1 | |
Completed |
NCT01146444 -
Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE)
|
N/A | |
Completed |
NCT03134222 -
Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
|
Phase 2 | |
Completed |
NCT01629784 -
Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus
|
N/A | |
Completed |
NCT00470912 -
Sunscreen RV 2457C in Photoinduced CLE
|
Phase 3 | |
Completed |
NCT01841619 -
IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus
|
Phase 0 | |
Completed |
NCT00523588 -
Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser
|
Phase 2 | |
Recruiting |
NCT06411106 -
Deep Phenotyping of Cutaneous Lupus Erythematosus
|
N/A | |
Terminated |
NCT01498406 -
Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus
|
Phase 2 | |
Completed |
NCT04647708 -
Study of M5049 in CLE and SLE Participants
|
Phase 1 | |
Completed |
NCT03817424 -
A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
|
Phase 1 | |
Active, not recruiting |
NCT03260166 -
Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT00317681 -
Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE)
|
Phase 2 | |
Completed |
NCT04781816 -
Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus
|
Phase 2 |